EPV-CoV-19 / EpiVax, University of Georgia - LARVOL DELTA

T-cell responses to highly conserved SARS-CoV-2 epitopes in Hispanic Americans receiving an mRNA COVID-19 vaccine. (PubMed, Hum Vaccin Immunother) - "This study reports the pre-clinical evaluation of peptides from EPV-CoV-19, a T cell epitope-based SARS-CoV-2 vaccine candidate, following spike-mRNA vaccination of a predominantly Hispanic American cohort...The addition of one new peptide to the vaccine design reestablished broad T cell epitope coverage. These findings underscore the importance of identifying highly conserved T cell epitopes for vaccine designs that target rapidly-mutating strains of emergent pathogens, while also documenting broad memory T cell response to the vaccine in a predominantly Hispanic American cohort."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

University Of Georgia works to develop a vaccine for coronavirus (GPB News) - “The University of Georgia is collaborating with Rhode Island based company EpiVax to develop a vaccine for COVID-19.”

Licensing / partnership